This company listing is no longer active
Spectrum Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Spectrum Pharmaceuticals has a total shareholder equity of $26.8M and total debt of $28.8M, which brings its debt-to-equity ratio to 107.6%. Its total assets and total liabilities are $107.7M and $80.9M respectively.
Key information
107.6%
Debt to equity ratio
US$28.84m
Debt
Interest coverage ratio | n/a |
Cash | US$56.14m |
Equity | US$26.81m |
Total liabilities | US$80.87m |
Total assets | US$107.68m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NTR's short term assets ($105.4M) exceed its short term liabilities ($38.9M).
Long Term Liabilities: NTR's short term assets ($105.4M) exceed its long term liabilities ($42.0M).
Debt to Equity History and Analysis
Debt Level: NTR has more cash than its total debt.
Reducing Debt: NTR's debt to equity ratio has increased from 12% to 107.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NTR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.